In patients with type 2 diabetes (T2D), the risks for gastroesophageal reflux disease (GERD) and GERD-related complications were greater with GLP-1 receptor agonist (RA) use than with SGLT2 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback